MedPath

Salbutamol

Generic Name
Salbutamol
Brand Names
Airomir, Airsupra, Combivent, Proair, Proventil, Ventolin
Drug Type
Small Molecule
Chemical Formula
C13H21NO3
CAS Number
18559-94-9
Unique Ingredient Identifier
QF8SVZ843E
Background

Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.

Indication

Salbutamol is indicated for (i) the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, reversible obstructive airway disease, and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor, and/or (ii) the acute prophylaxis against exercise-induced bronchospasm and other stimuli known to induce bronchospasm.

Associated Conditions
Asthma, Asthmatic Bronchitis, Bronchial Asthma, Bronchoconstriction, Bronchospasm, Chronic Asthma, Chronic Bronchitis, Cough, Emphysema, Exacerbation of asthma, Exercise-Induced Bronchospasm, Hyperkalemia, Wheezing, Excess mucus or phlegm
Associated Therapies
Airway secretion clearance therapy, Bronchodilation

Evaluating Bronchodilator Response in Patients With Bronchiectasis

Not Applicable
Recruiting
Conditions
Cystic Fibrosis
Primary Immune Deficiency
Bronchiolitis Obliterans
Bronchiectasis
Primary Ciliary Dyskinesia
Interventions
Diagnostic Test: spirometry
Drug: Salbutamol
Drug: placebo
First Posted Date
2023-07-06
Last Posted Date
2023-07-06
Lead Sponsor
Rambam Health Care Campus
Target Recruit Count
96
Registration Number
NCT05932316
Locations
🇮🇱

Rambam Health Campus, Haifa, Israel

Effect of Salbutamol on Walking Capacity in Ambulatory ALS Patients

Phase 2
Not yet recruiting
Conditions
Walking Capacity
Amyotrophic Lateral Sclerosis
Interventions
Drug: Placebo
Drug: Salbutamol
First Posted Date
2023-05-16
Last Posted Date
2024-04-12
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Target Recruit Count
36
Registration Number
NCT05860244
Locations
🇫🇷

Hôpital Pitié Salpêtrière, Paris, France

Treating Exacerbations of Asthma With Oral Montelukast in Children

Phase 2
Recruiting
Conditions
Status Asthmaticus
Interventions
First Posted Date
2023-04-19
Last Posted Date
2024-05-14
Lead Sponsor
Vanderbilt University Medical Center
Target Recruit Count
90
Registration Number
NCT05819541
Locations
🇺🇸

Monroe Carell Jr. Children's Hospital at Vanderbilt, Nashville, Tennessee, United States

The Effect of Nebulized Epinephrine in Asthma Exacerbation in Pediatric Age Group With the Standard Treatment Compared to Standard Treatment Using Improvement PRAM Score as a Primary Outcome

Phase 4
Recruiting
Conditions
Asthma in Children
Shortness of Breath
Epinephrine Causing Adverse Effects in Therapeutic Use
Salbutamol Adverse Reaction
Interventions
First Posted Date
2022-12-29
Last Posted Date
2024-04-09
Lead Sponsor
Oman Medical Speciality Board
Target Recruit Count
30
Registration Number
NCT05667727
Locations
🇴🇲

Royal Hospital, Muscat, Oman

INhaled Salbutamol vs Placebo for the Treatment of Acute IgE-mediated Abdominal Pain From Allergic Food REactions

Phase 3
Recruiting
Conditions
IgE-mediated Abdominal Pain
Interventions
Drug: Salbutamol
Drug: Placebo
First Posted Date
2022-12-15
Last Posted Date
2024-11-28
Lead Sponsor
Philippe Bégin
Target Recruit Count
498
Registration Number
NCT05653024
Locations
🇨🇦

CHU Sainte-Justine, Montréal, Quebec, Canada

Nebulized Salbutamol Facilitate Management of Hyperkalemia Postreperfusion During Liver Transplantation

Not Applicable
Not yet recruiting
Conditions
Liver Transplantation
Interventions
Drug: salbutamol
Drug: Insulin
First Posted Date
2022-10-21
Last Posted Date
2022-10-21
Lead Sponsor
First Affiliated Hospital Xi'an Jiaotong University
Target Recruit Count
100
Registration Number
NCT05589441

Role of Parasympathetic Activity in Mild to Severe Asthma With Fixed Airway Obstruction (PARASMA Study)

Not Applicable
Recruiting
Conditions
Asthma
Airway Remodeling
Airway Obstruction
Parasympathetic Nervous System Diseases
Interventions
First Posted Date
2022-09-22
Last Posted Date
2024-02-20
Lead Sponsor
Hat Yai Medical Education Center
Target Recruit Count
60
Registration Number
NCT05550402
Locations
🇹🇭

Hatyai Hospital, Hat Yai, Songkhla, Thailand

the Inhaled β2-adrenergic Receptor Agonist for Transient Tachypnoea of the Newborn (the REFSAL Trial)

Phase 3
Recruiting
Conditions
PPHN
TTN
Respiratory Failure
Interventions
Drug: 0,9% Chloride Sodium
Drug: Salbutamol
First Posted Date
2022-09-02
Last Posted Date
2024-04-18
Lead Sponsor
Medical University of Warsaw
Target Recruit Count
608
Registration Number
NCT05527704
Locations
🇵🇱

Medical University of Warsaw, Warsaw, Poland

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Salbutamol vs Long-acting Muscarinic Antagonists

Active, not recruiting
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
First Posted Date
2022-07-14
Last Posted Date
2023-07-18
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
124117
Registration Number
NCT05457868
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Levalbuterol Compared to Albuterol Regarding Cardiac Side Effects and Potassium Lowering Effects.

Phase 4
Conditions
Hyperkalemia
Interventions
First Posted Date
2021-12-30
Last Posted Date
2021-12-30
Lead Sponsor
University of Aleppo
Target Recruit Count
30
Registration Number
NCT05173584
Locations
🇸🇾

Aleppo University Hospital, Aleppo, Aleppo Provice, Syrian Arab Republic

© Copyright 2025. All Rights Reserved by MedPath